Sinclair North America

“At our company, we believe that our people are our most valuable asset, and it is our mission to create a culture that supports and nurtures them.“ Andrea Trofimuk, CEO of Sinclair North America

NEW YORK (PRWEB)
May 11, 2023

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That’s something to be proud of. In today’s market, leaders must ensure they’re allowing employees to have a voice and be heard. That’s paramount. Top Workplaces do this, and it pays dividends.”

Being awarded a Top Workplaces company recognizes Sinclair North America’s commitment to creating a positive and supportive work environment for its employees, fostering a culture of innovation, and upholding high standards of ethics and integrity. “We are honored and grateful to be recognized as a top workplace. said Andrea Trofimuk, CEO of Sinclair North America. “

“At our company, we believe that our people are our most valuable asset, and it is our mission to create a culture that supports and nurtures them.“

Sinclair North America has a long-standing reputation for excellence in post-sales support, with a focus on providing creative solutions and tools for its customers. The company has a dedicated team of professionals who are committed to delivering exceptional service and quality products to aesthetic providers in the US & Canada.

“We are committed to building a workplace where camaraderie, professional growth, autonomy, and transparency are not just buzzwords, but fundamental pillars of our ethos. This nomination is a testament to the hard work and dedication of our employees, and we will continue to invest in their success and well-being.” Said Mrs. Trofimuk.

The recognition as a top workplace is a testament to Sinclair North America’s commitment to its employees and its customers. Sinclair looks forward to building a more supportive and positive work environment in the future than already exists.

Sinclair is an international company operating in the fast-growing, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in North America, the EU markets, Brazil, Mexico, Colombia, UAE, Hong Kong and South Korea and a network of international distributors.

Share article on social media or email:

The contest is open to all people in the United States who have been diagnosed with kidney disease, have had a kidney transplant, or are on dialysis.

Lori Hartwell, founder and president of RSN, says, “One of the strategies I use to cope with challenges is to engage in the creative process. When I am involved in doing something creative, or even when I watch someone who is involved, I feel relaxed. It helps me live in the moment.”

GLENDALE, Calif. (PRWEB)
May 11, 2023

Renal Support Network (RSN) is pleased to announce the theme of its 21st annual essay contest. This year, it’s all about creativity, and writers are asked to address the following question: “How do you use your creativity to help cope with kidney disease?” The contest is open to all people in the United States who have been diagnosed with kidney disease, have had a kidney transplant, or are on dialysis.

RSN’s Essay Contest was originally established in 2002. Since then, thousands of essays have been submitted by people living with CKD. The contest gives those who live with chronic kidney disease (CKD) the opportunity to tell their story.

Lori Hartwell, founder and president of RSN, says, “When our kidneys fail, we must embrace a new life and learn to live with the challenges we face every day. As individuals with a chronic disease, how do we deal with the bumps in the road that seem to continually appear before us? One of the strategies I use to cope with those challenges is to engage in the creative process. When I am involved in doing something creative, or even when I watch someone who is involved, I feel relaxed. It helps me live in the moment.”

Contest winners receive cash prizes: First Place, $500; Second Place, $300; and Third Place, $100. For submissions to be accepted, they must be typed and not exceed 750 words. The submission deadline is August 10, 2023. Winners will be announced the week of September 24, 2023. Winning essays will be published on RSN’s website, RSNHope.org, and will also be featured in RSN’S publication, KidneyTalk® Magazine.

You can read 20 years of essays by previous winners on the website RSNhope.org/essay-contest/.

To learn more about the contest rules and how to submit your essay, and download a flyer to share https://www.rsnhope.org/essay-contest.

RSN would like to thank their corporate partners who helped support this patient engagement writing contest: Akebia, Fresenius Kidney Care, and U.S. Renal Care.

The Renal Support Network (RSN) is a nonprofit organization founded by Lori Hartwell in 1993. RSN’s hopeful and life-enriching programs help people, and their families deal with kidney disease, whether they are in the early stages of the disease, on dialysis, or have had a transplant. Hartwell’s mission is to help them cope and give them hope. Hartwell suffered kidney failure at the age of 2. She survived 50-plus surgeries and was on dialysis for 13 years. She is now living with her fourth kidney transplant. Hartwell founded RSN to encourage her peers to develop the skills and knowledge necessary to navigate this illness. To this day, Hartwell continues to serve as president of RSN, the leading organization in engaging people who have kidney disease through its vast reach and prolific library of documented patient experiences. Visit http://www.RSNhope.org to learn more.

Share article on social media or email:

Join this webinar to learn about the benefits of this approach for: Expansion and activation of memory B cells.

TORONTO (PRWEB)
May 11, 2023

Since the first therapeutic monoclonal antibody was approved by the US Food and Drug Administration (FDA) in 1986, the field of antibody therapy development has increased, yet it continues to face many challenges. The scarcity of antigen-specific B cells is one of the hurdles scientists face early-on when developing a monoclonal antibody to treat cancer, autoimmune disease or infection. In this webinar, learn about enhancing antibody discovery with novel strategies — such as the one developed by Single Cell Technology — that enable the accelerated generation of neutralizing monoclonal antibodies from influenza-vaccinated individuals.

Join this webinar to learn about the benefits of this approach for: Expansion and activation of memory B cells; Isolation of antigen-specific memory B cells from vaccinated individuals with faster, gentler and safer microchip-based cell sorting; Capture and sequencing of antigen-specific antibodies using a novel platform for antibody discovery that uses next-gen sequencing technology; And creation, expression and cross-reactivity testing of recombinant antibodies.

Join Chun-Nan Chen, Chief Executive Officer, Single Cell Technology; Allison Schulkins, Chief Operating Officer, Single Cell Technology; and Crystal Montoya, Senior Marketing Product Manager, Miltenyi Biotec, for the live webinar on Wednesday, May 31, 2023, at 3pm EDT (12pm PDT).

For more information, or to register for this event, visit Accelerate Novel Antibody Discovery with Antigen-Specific B Cell Isolation.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Learn practical guidance and actionable insight for addressing the complexity of study start-up and execution outside the traditional cell and gene therapy sites.

TORONTO (PRWEB)
May 11, 2023

Thanks to scientific advances and resource investment, the cell and gene therapy pipeline continues to expand. Current research infrastructure, however, cannot support the increased clinical development. The use of exploratory endpoints is growing, and often, small patient populations are difficult to identify, alongside challenges with recruiting diverse patient populations. Meanwhile, sites are understaffed and overwhelmed.

To support sponsors and their partners to innovate in this growing, but uncertain space Parexel presents New Medicines, Novel Insights which is their perspective on speeding life-changing medicines to market. With a focus on cell and gene therapies, the second report in the series launches in mid-May and explores factors that are critical to therapy development success, accounting for the market and operational landscape in 2023.

In this webinar, the speakers explore one of the topical clinical development perspectives contained within the report, the challenges and opportunities of moving trials into the community. Learn practical guidance and actionable insight for addressing the complexity of study start-up and execution outside the traditional cell and gene therapy sites.

Join this webinar to learn how moving cell and gene therapy trials from overloaded research centers to communities can increase diversity, expand patient access and relieve site fatigue. Hear perspectives from Parexel’s site and project leadership experts, and Chris Jenkins from Clinical Biosafety Services, all working together to expand into community-based settings.

Join Alberto Grignolo (Moderator), PhD, Corporate Vice President, Corporate Strategy & Thought Leadership, Parexel; Chris Jenkins, PhD, MPH, Principal Partner & Chief Gene Therapy Biosafety Officer, Clinical Biosafety Services; Kathy Scott, Associate Director, Site Alliances, Parexel; and Shannon Macquarrie, Senior Vice President, Project Leadership, Parexel, for the live webinar on Thursday, June 1, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Moving Cell and Gene Therapy Trials into the Community: Challenges and Opportunities.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Register for this webinar on the EU CTR process to gain valuable insights on how to avoid pitfalls in the early phase clinical trial submissions and navigate the regulatory review process efficiently.

TORONTO (PRWEB)
May 11, 2023

This webinar will take attendees through the lessons learned and timelines to EU CTR approval based on experiences so far.

The new EU Clinical Trials Regulation (CTR) aims to create a more favourable environment for research in Europe, as well as maintain the highest level of standards for patient safety, and increased transparency of clinical trial information. With any new regulatory review process there can be a period of adjustment as sponsors become accustomed to the new procedures and timelines.

During this webinar the featured speakers will outline the EU CTR process, sharing their experience of early phase clinical trial submissions so far. The webinar will offer insights into where efficiencies can be gained, pitfalls to avoid and how one can work together with their CRO to leverage the EU CTR as an opportunity to improve processes, whilst complying with legal responsibilities.

Register for this webinar on the EU CTR process to gain valuable insights on how to avoid pitfalls in the early phase clinical trial submissions and navigate the regulatory review process efficiently.

Join experts from ICON, Vicki Lassonidou, Director, Regulatory Affairs; and Dr. Emma Meijer, Director, Project Management, for the live webinar on Thursday, June 1, 2023, at 10am EDT (4pm CEST/EU-Central).

For more information, or to register for this event, visit Navigating the new EU CTR regulations in early phase clinical trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email: